Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Letters to the Editor

Correspondence re: C. Chen et al., CYP2D6 Genotype and the Incidence of Anal and Vulvar Cancer. Cancer Epidemiol. Biomark. Prev., 8: 317–321, 1999

Stephen S. Hecht
Stephen S. Hecht
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published September 1999
  • Article
  • Info & Metrics
  • PDF
Loading

The paper by Chen et al. (1) proposes to test the hypothesis that individuals with reduced levels of CYP2D6 (debrisoquine 4-hydroxylase) activity will have a lower risk of anogenital cancer associated with exposure to the tobacco-specific nitrosamine NNK.1 NNK is a potent carcinogen associated with tobacco-induced cancers in humans. Their rationale is that CYP2D6 can metabolically activate NNK to intermediates that bind to DNA and initiate carcinogenesis. Therefore, individuals with lower activity will have lower risk. In my opinion, this hypothesis is weak because CYP2D6 is an ineffective catalyst of NNK metabolic activation.

The role of CYP2D6 in NNK metabolic activation has been investigated directly in three studies. In the first, Crespi et al. (2) showed that a B-lymphoblastoid cell line stably expressing CYP2D6 cDNA activated NNK to a mutagen, but the activity was substantially less than that of similar cell lines expressing CYP2A3 and CYP1A2 and was similar to a cell line expressing CYP2E1. In a second study, the metabolism of NNK was investigated using cell lysate protein from HepG2 cells in which 12 human CYP forms—1A2, 2A6, 2B7, 2C8, 2C9, 2D6, 2E1, 2F1, 3A3, 3A4, 3A5, and 4B1—were expressed (3) . CYP1A2 had, by far, the highest activity; that of CYP2D6 was the same as control HepG2 cells. In the third study, a new cell line containing two CYP2D6 transcriptional cassettes and having 3-fold higher CYP2D6 activity than that used in the first study was used to analyze NNK metabolism and mutagenicity (4) . NNK mutagenicity was again observed, but the turnover number for NNK metabolism was relatively low, leading the authors to conclude that “one would expect a minor role for CYP2D6 in human hepatic metabolism of NNK.” Collectively, these studies demonstrate that CYP2D6 is a relatively poor catalyst of NNK metabolic activation. Currently, available evidence indicates that human CYP1A2, 2A6, 3A4, and 2E1 are substantially better catalysts of NNK metabolic activation than CYP2D6 (5) .

The relationship between CYP2D6 activity and lung cancer is inconsistent and inconclusive, based on a large number of published studies (6) . The study of Chen et al. (1) indicates that there is no relationship between CYP2D6 activity and anogenital cancer. These findings do not detract from the potential importance of NNK in tobacco-induced cancer at these sites because CYP2D6 is not an effective catalyst of NNK metabolic activation.

Footnotes

  • ↵1 The abbreviation used is: NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.

  • ↵1 The abbreviation used is: NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.

    • Accepted June 15, 1999.
    • Received May 3, 1999.

References

  1. ↵
    Chen C., Cook L. S., Li X-Y., Hallagan S., Madeleine M. M., Daling J. R., Weiss N. S. CYP2D6 genotype and the incidence of anal and vulvar cancer. Cancer Epidemiol. Biomark. Prev., 8: 317-321, 1999.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Crespi C. L., Penman B. W., Gelboin H. V., Gonzalez F. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis (Lond.), 12: 1197-1201, 1991.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Smith T. J., Guo Z. Y., Gonzalez F. J., Guengerich F. P., Stoner G. D., Yang C. S. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res., 52: 1757-1763, 1992.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Penman B. W., Reece J., Smith T., Yang C. S., Gelboin H. V., Gonzalez F. J., Crespi C. L. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics, 3: 28-29, 1993.
    OpenUrlCrossRefPubMed
  5. ↵
    Hecht S. S. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol., 11: 559-603, 1998.
    OpenUrlCrossRefPubMed
  6. ↵
    Spivack S. D., Fasco M. J., Walker V. E., Kaminsky L. S. The molecular epidemiology of lung cancer. Crit. Rev. Toxicol., 27: 319-365, 1997.
    OpenUrlPubMed

Reply

We believe that it was reasonable for us to have investigated the possibility that differences in CYP2D6 genotype could be associated with differences in risk of anogenital tumors (1)— and for others to have done similar studies of lung tumors—even with the knowledge that CYP1A2, 2A6, 2E1, and 3A4 have been shown to activate NNK1 to a greater or equal extent than CYP2D6 in B-lymphoblastoid ,(2 , 3) and HepG2 (4) cell lines. This is because: (a) The relative importance of metabolism of NNK by the liver versus that by the anogenital tissues is unknown at this time. Because of the short half-lives of NNK metabolites, metabolism of NNK in target tissue might be quantitatively important. (b) The relative concentrations of CYP2D6, 1A2, 2A6, 2E1, and 3A4 in anogenital tissues are unknown at present, making it difficult to predict the relative importance in NNK activation of these enzymes.

We agree with Hecht’s conclusion that our “findings do not detract from the potential importance of NNK in tobacco-induced cancer” (5) . We tried to say as much in our article (1) , i.e., that “… enzymes other than CYP2D6, such as CYP2A6 and CYP2E1, are capable of metabolizing nitrosamines” and that, our findings notwithstanding, it is likely that “tobacco-specific nitrosamines play a role in the etiology of anal and vulvar cancers.” Unfortunately for us, it has been easier to identify this hypothesis involving other P450 enzymes than it has been to convince a reluctant study section that we should be awarded funds to test it.

Footnotes

    • Accepted June 15, 1999.
    • Received June 3, 1999.

References

  1. ↵
    Chen C., Cook L. S., Li X-Y., Hallagan S., Madeleine M. M., Daling J. D., Weiss N. S. CYP2D6 genotype and the incidence of anal and vulvar cancer. Cancer Epidemiol. Biomark. Prev., 8: 317-321, 1999.
  2. ↵
    Crespi C. L., Penman B. W., Gelboin H. V., Gonzalez F. J. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450 including the polymorphic human cytochrome P4502D6. Carcinogenesis (Lond.), 12: 1197-1201, 1991.
  3. ↵
    Penman B. W., Reece J., Smith T., Yang C. S., Gelboin H. V., Gonzalez F. J., Crespi C. L. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics, 3: 28-39, 1993.
  4. ↵
    Smith T. J., Guo Z., Gonzalez F. J., Guengerich F. P., Stoner G. D., Yang C. S. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res., 52: 1757-1763, 1992.
  5. ↵
    Hecht, S. S., Correspondence re: C. Chen et al., CYP2D6 genotype and the incidence of anal and vulvar cancer. Cancer Epidemiol. Biomark. Prev., 8 317–321, 1999. Cancer Epidemiol. Biomark. Prev., 8 839, 1999.
PreviousNext
Back to top
September 1999
Volume 8, Issue 9
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Correspondence re: C. Chen et al., CYP2D6 Genotype and the Incidence of Anal and Vulvar Cancer. Cancer Epidemiol. Biomark. Prev., 8: 317–321, 1999
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Correspondence re: C. Chen et al., CYP2D6 Genotype and the Incidence of Anal and Vulvar Cancer. Cancer Epidemiol. Biomark. Prev., 8: 317–321, 1999
Stephen S. Hecht
Cancer Epidemiol Biomarkers Prev September 1 1999 (8) (9) 839-840;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Correspondence re: C. Chen et al., CYP2D6 Genotype and the Incidence of Anal and Vulvar Cancer. Cancer Epidemiol. Biomark. Prev., 8: 317–321, 1999
Stephen S. Hecht
Cancer Epidemiol Biomarkers Prev September 1 1999 (8) (9) 839-840;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
    • Footnotes
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Copy Number Variation and Ovarian Cancer Risk—Letter
  • Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk—Response
  • Shift Work, Chronotype, and Cancer Risk—Response
Show more Letters to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement